Revenues for the three months ended Dec. 31 were $2.62 billion, up from $2.29 billion in Q4 2023 and above the consensus Wall Street estimate of $2.58 billion.
We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click ...
MarketBeat on MSN3d
Health-Tech Revival: 3 Stocks Set for a Big 2025 ReboundThe healthcare industry is undergoing rapid transformation, driven by advancements in technology, artificial intelligence, ...
After a dip in the wake of the release of UnitedHealth Group's Q4 2024 earnings figures, shares in the company and other ...
Q4 2024 Earnings Call Transcript January 23, 2025 Elevance Health Inc. beats earnings expectations. Reported EPS is $3.84, expectations were $3.8. Operator: Ladies and gentlemen, thank you for ...
Barclays raised the firm’s price target on Elevance Health (ELV) to $512 from $501 and keeps an Overweight rating on the shares post the Q4 ...
Mizuho Securities analyst Ann Hynes has maintained their bullish stance on ELV stock, giving a Buy rating on January 16.Invest with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback